Luca Gattinoni News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Luca gattinoni. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Luca Gattinoni Today - Breaking & Trending Today

Rejuvenation: Innovative Technology to Improve T cell Antitumor Properties Through Partial Reprogramming

Rejuvenation: Improving T-cell Antitumor Properties

. | June 15, 2023 ....

United States , New York , Gary Lee , Melanie Styers Verascity , Kriti Bahl , Takuya Maeda , Luca Gattinoni , Yasuhiro Yamazaki , Jessica Fioravanti , Naritaka Tamaoki , Raul Vizcardo , Shobha Potluri , Burak Kutlu , Nicholasp Restifo Lyell Immunopharma Inc , Oclock Foundation , Maria Romanova Molecular House Inc , Madison Fagan Boldscience Inc , Antitumor Properties , Lyell Immunopharma Inc , Improvingt Cell Antitumor Properties , Yin Huang , Lyell Immunopharma , South San Francisco , Retainedt Cell , Maria Romanova , Molecular House ,

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021

Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021
News provided by
Share this article
Share this article
SAN DIEGO, May 11, 2021 /PRNewswire/ Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021.
We are encouraged by our continued progress in first quarter of 2021, building on the accomplishments from the prior year as we moved multiple programs forward to important inflection points, including our ongoing P-BCMA-101 and P-PSMA-101 CAR-T programs, on which we plan to provide further clinical updates later in the year, said Eric Ostertag, M.D., Ph.D., Chief Executive Officer of Poseida. Additionally, we intend to advance two INDs in our allogeneic CAR-T por ....

United States , Luca Gattinoni , Eric Ostertag , J Joseph Melenhorst , Christine Brown , Dc Program , Perelman School Of Medicine , Poseida Therapeutics Inc , Prnewswire Poseida Therapeutics Inc , Development Expenses , American Society Of Gene , Adjunct Associate Professor Of Pathology Laboratory Medicine , University Of Regensburg , Regensburg Center , Exchange Commission , Stage Development Programs , University Of Pennsylvania , Virtual Healthcare Conference , Program Updates , Chief Executive Officer , Operational Updates , Immuno Oncology Scientific Advisory Board , Carl June , Functional Immune Cell Modulation , Interventional Immunology , Heritage Provider Network Professor ,

Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board

Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

Eric Ostertag , Luca Gattinoni , J Joseph Melenhorst , Christine Brown , Regensburg Center , University Of Regensburg , Perelman School Of Medicine , Poseida Therapeutics Inc , Exchange Commission , University Of Pennsylvania , Adjunct Associate Professor Of Pathology Laboratory Medicine , Functional Immune Cell Modulation , Interventional Immunology , Heritage Provider Network Professor , Hope Comprehensive Cancer Center , Adjunct Associate Professor , Laboratory Medicine , Perelman School , Scientific Advisory Board , Chief Executive Officer , Poseida Therapeutics , Site Specific Gene Editing System , Private Securities Litigation Reform Act , எரிக் ஆஸ்டர்டெக் , கிறிஸ்டின் பழுப்பு , பெரல்மேன் பள்ளி ஆஃப் மருந்து ,